测试将抗癌药物 BAY 1895344 添加到 FOLFIRI 的常规化疗中治疗晚期或转移性胃肠癌
ATR 抑制剂 BAY 1895344 联合 FOLFIRI 治疗胃肠道恶性肿瘤的 I/Ib 期试验,重点是转移性结直肠癌和胃/胃食管癌
This phase I trial investigates the best dose, possible benefits and/or side effects of BAY 1895344 in combination with FOLFIRI in treating patients with stomach or intestinal cancer that that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has spread from where it first started (primary site) to other places in the body (metastatic). BAY 1895344 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as irinotecan, fluorouracil, and leucovorin, (called FOLFIRI in short) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BAY 1895344 in combination with FOLFIRI may help shrink advanced or metastatic stomach and/or intestinal cancer.
研究概览
地位
地位
条件
条件
干预/治疗
干预/治疗
详细说明
PRIMARY OBJECTIVE:
I. Determine the safety and maximum tolerated dose (MTD) of elimusertib (BAY 1895344) with leucovorin calcium, fluorouracil, and irinotecan hydrochloride (FOLFIRI).
SECONDARY OBJECTIVES:
I. To observe and record anti-tumor activity by overall response rate (ORR), progression-free survival (PFS), and overall survival (OS).
II. Determine the response and clinical benefit rate (complete response + partial response + stable disease) of BAY 1895344 with FOLFIRI in colorectal and gastric/gastroesophageal cancers.
III. Evaluate tumor and peripheral blood mononuclear cell (PBMC) deoxyribonucleic acid (DNA) damage signaling in the context of the chemotherapy backbone alone and when combined with BAY 1895344.
IV. Evaluate the pharmacokinetics (PK) profile of fluorouracil (5-FU) and irinotecan.
V. Evaluate the PK profile of BAY 1895344. VI. Evaluate the relationship between ATM status by immunohistochemistry (IHC) and clinical efficacy of the BAY 1895344/FOLFIRI combination.
EXPLORATORY OBJECTIVES:
I. Evaluate the exposure-response relationship between drug exposures and toxicity and response, and UGT1A1 genotype.
II. Evaluate the relationship between tumor mutations and clinical efficacy of the BAY 1895344/FOLFIRI combination.
OUTLINE: This is a dose-escalation study of elimusertib, irinotecan, and fluorouracil with fixed-dose leucovorin followed by a dose-expansion study.
Patients receive elimusertib orally (PO) once daily (QD) on days 2, 3, 16, and 17 and irinotecan hydrochloride intravenously (IV) over 90 minutes, fluorouracil IV over 46 hours, and leucovorin calcium IV on days 1 and 15. Cycles repeat every 28 day in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy during screening and on study and blood sample collection and imaging throughout the study.
After completion of study treatment, patients are followed up for 30 days and then every 3 months for up to 1 year or until their disease gets worse or they begin a new treatment for their cancer.
研究类型
研究类型
注册 (实际的)
注册
阶段
阶段
- 阶段1
联系人和位置
学习地点
-
-
California
-
Duarte、California、美国、91010
- City of Hope Comprehensive Cancer Center
-
-
Maryland
-
Bethesda、Maryland、美国、20892
- National Institutes of Health Clinical Center
-
Bethesda、Maryland、美国、20892
- National Cancer Institute Developmental Therapeutics Clinic
-
-
Missouri
-
City of Saint Peters、Missouri、美国、63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur、Missouri、美国、63141
- Siteman Cancer Center at West County Hospital
-
St Louis、Missouri、美国、63110
- Washington University School of Medicine
-
St Louis、Missouri、美国、63129
- Siteman Cancer Center-South County
-
St Louis、Missouri、美国、63136
- Siteman Cancer Center at Christian Hospital
-
-
New York
-
New York、New York、美国、10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15232
- UPMC Hillman Cancer Center
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
For Dose Escalation: Patients must have histologically or cytologically confirmed advanced or metastatic gastrointestinal (GI) cancers with Response Evaluation Criteria in Solid Tumors 1.1 (RECIST1.1) measurable disease who have progressed on at least one prior treatment for metastatic disease and for whom FOLFIRI is considered a reasonable treatment option. Patients with mismatch repair deficiency should have progressed on immunotherapy
-
For Dose Expansion: Patients must have either:
- Colorectal cancer who have previously progressed on irinotecan and tolerated an irinotecan dose equal to or greater than the recommended phase 2 dose (RP2D). If they have mismatch repair deficiency they should have progressed on immunotherapy OR
- Gastroesophageal cancer who have progressed on at least one first-line therapy for metastatic disease. If they have mismatch repair deficiency they should have progressed on immunotherapy
-
For Dose Expansion: Patients be willing to undergo biopsies for research purposes only. The accessible tumor can be the primary or metastatic tumor site. Both research biopsies should be taken from the same tumor site
-
Patients must have progressive disease on at least first-line therapy for metastatic disease. Previous treatment with irinotecan is allowed
-
Age >= 18 years. Because no dosing or adverse event data are currently available on the use of BAY 1895344 in combination with FOLFIRI in patients <18 years of age, children are excluded from this study
-
Eastern Cooperative Oncology Group (ECOG) performance status =< 1
-
Leukocytes >= 3,000/mcL
-
Absolute neutrophil count >= 1,500/mcL
-
Platelets >= 100,000/mcL
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN
-
Glomerular filtration rate (GFR) >= 60 mL/min/1.73 m^2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
-
International normalization ratio (INR) =< 1.5 × ULN unless participant is receiving anticoagulant therapy, in which case prothrombin time (PT) or activated partial thromboplastin time (aPTT) should be within expected therapeutic range of anticoagulants. If patient has a new diagnosis of venous thromboembolism (VTE), then patient should be appropriately anticoagulated with low molecular weight heparin (LMWH) or direct acting oral anticoagulants (DOACs) and be clinically stable for at least 1 week post treatment onset
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy, that does not interact with study therapy, with undetectable viral load within 6 months are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy that does not interact with study therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load and HCV therapy does not interact with study therapy
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
-
The effects of BAY 1895344 on the developing human fetus are unknown. For this reason and because DNA-damage response inhibitors agents as well as other therapeutic agents used in this trial, 5-FU and irinotecan, are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for 6 months after completion of BAY 1895344 administration
- Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of study treatment administration
-
Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible
Exclusion Criteria:
- Patients with a history of prior treatment with an ATR inhibitor
- Patients with a history of other malignancy that could affect compliance with the protocol or interpretation of the results
- Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
- Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia
- Patients who are receiving any other investigational agents
- History of hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to BAY 1895344, 5-FU, leucovorin, or irinotecan. Patient eligibility can be discussed with the primary investigator (PI) if prior reactions do not seem to warrant excluding the patient
- Patients receiving any medications that are substrates of CYP3A4 with a narrow therapeutic window or strong inhibitors/inducers of CYP3A4 are ineligible, if they cannot be transferred to alternative medication. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
- Patients with uncontrolled intercurrent illness
- Patients with psychiatric illness/social situations that would limit compliance with study requirements
- Gastrointestinal pathology or history that adversely impact the ability to take or absorb oral medication
- Pregnant women are excluded from this study because BAY 1895344 as a DNA-damage response inhibitor may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with BAY 1895344 breastfeeding should be discontinued if the mother is treated with BAY 1895344 and for 4 months after end of treatment. These potential risks may also apply to other agents used in this study
- Patients who were unable to tolerate prior irinotecan treatment are excluded from this study
- Patients with a corrected QT (QTc) interval >= 470 msec are excluded from this study
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:Treatment (elimusertib, FOLFIRI)
Patients receive elimusertib PO QD on days 2, 3, 16, and 17 and irinotecan hydrochloride IV over 90 minutes, fluorouracil IV over 46 hours, and leucovorin calcium IV on days 1 and 15. Cycles repeat every 28 day in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy during screening and on study and blood sample collection and imaging throughout the study. |
Given IV
其他名称:
Undergo blood sample collection
其他名称:
Undergo tumor biopsy
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Undergo imaging
其他名称:
Given PO
其他名称:
|
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Maximum Tolerated Dose (MTD) of Elimusertib (BAY 1895344) in Combination With Irinotecan, Fluorouracil, and Leucovorin (FOLFIRI)
大体时间:Up to 28 days
|
A BOIN - Bayesian Optimal intervals trial design will be used to determine the MTD. |
Up to 28 days
|
|
Patients Who Experienced DLTs
大体时间:Up to 28 days
|
Percentage of Patients Who Experienced Dose Limiting Toxicities (DLTs) , per CTCAE v5.0 |
Up to 28 days
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
12-month Progression-free Survival (PFS) - Total Population
大体时间:At 12 months
|
Percentage of patients with Progression-free survival (PFS) will be estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment to time of progression or death, whichever occurs first. Per RECIST v1.1 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
At 12 months
|
|
24-month Progression-free Survival (PFS) - Total Population
大体时间:At 24 months
|
Percentage of patients with Progression-free survival (PFS) will be estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment to time of progression or death, whichever occurs first. Per RECIST v1.1 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
At 24 months
|
|
Cmax of Irinotecan (Lead in)
大体时间:Up to 1 year post treatment
|
Concentration Maximum (Cmax) of irinotecan and 5FU in Lead-in phase. |
Up to 1 year post treatment
|
|
AUC of Irinotecan (Lead in)
大体时间:Up to 1 year post treatment
|
Area Under the Curve (AUC) of irinotecan and 5FU in Lead-in phase. |
Up to 1 year post treatment
|
|
AUC of 5FU (Lead-in)
大体时间:Up to 1 year post treatment
|
Area Under the Curve (AUC) of irinotecan and 5FU in Lead-in phase. |
Up to 1 year post treatment
|
|
Cmax of Irinotecan (Combination)
大体时间:Up to 1 year post treatment
|
Concentration Maximum (Cmax) of irinotecan in Combination (BAY + 5FU and Irinotecan) phase. |
Up to 1 year post treatment
|
|
AUC of Irinotecan (Combination)
大体时间:Up to 1 year post treatment
|
Area Under the Curve (AUC) of irinotecan in Combination (BAY + 5FU and Irinotecan) phase. |
Up to 1 year post treatment
|
|
AUC of 5FU (Combination)
大体时间:Up to 1 year post treatment
|
Area Under the Curve (AUC) of 5FU in Combination (BAY + 5FU and Irinotecan) phase |
Up to 1 year post treatment
|
|
Cmax of BAY 1895344
大体时间:Up to 1 year post treatment
|
Concentration maximum (Cmax) of BAY 1895344. |
Up to 1 year post treatment
|
|
AUC-6 of BAY 1895344
大体时间:Up to 1 year post treatment
|
Area Under the Curve of BAY 1895344. |
Up to 1 year post treatment
|
|
AUC of BAY 1895344
大体时间:Up to 1 year post treatment
|
AUC of BAY 1895344 |
Up to 1 year post treatment
|
|
Overall Response Rate (ORR)
大体时间:Up to 1 year post treatment
|
Percent probability of Complete Response (CR) or Partial Response (PR) per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) with reduction in short axis to <10 mm; PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. |
Up to 1 year post treatment
|
|
Clinical Benefit Rate (CBR)
大体时间:Up to 1 year post treatment
|
Percent probability of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) with reduction in short axis to <10 mm; PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters or SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters. |
Up to 1 year post treatment
|
|
Best Response
大体时间:Up to 1 year post treatment
|
Number of patients with Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD) per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) with reduction in short axis to <10 mm; PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters or SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
Up to 1 year post treatment
|
|
Progression-free Survival (PFS) - by Dose Level
大体时间:Up to 24 months post treatment
|
Median PFS will be estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions. Measured from start of treatment to time of progression or death, whichever occurs first. Per RECIST v1.1 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
Up to 24 months post treatment
|
|
12-month Progression-free Survival (PFS) - by Dose Level
大体时间:At 12 months
|
Proportion of patients with Progression-free survival (PFS) will be estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment to time of progression or death, whichever occurs first. Per RECIST v1.1 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
At 12 months
|
|
24-month Progression-free Survival (PFS) - by Dose Level
大体时间:At 24 months
|
Proportion of patients with Progression-free survival (PFS) will be estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment to time of progression or death, whichever occurs first. Per RECIST v1.1 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
At 24 months
|
|
Progression-free Survival (PFS) - Total Population
大体时间:Up to 24 months post treatment
|
Median PFS will be estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions. Measured from start of treatment to time of progression or death, whichever occurs first. Per RECIST v1.1 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
Up to 24 months post treatment
|
|
Overall Survival (OS) - by Dose Level
大体时间:Up to 24 months post treatment
|
Median number of months patients are alive from start of treatment until death while on study will be estimated within disease cohorts (KM estimator), with 95% CI. |
Up to 24 months post treatment
|
|
12- Month Overall Survival (OS) - By Dose Level
大体时间:At 12 months
|
Proportion of patients alive estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment to time of death. |
At 12 months
|
|
24-month Overall Survival (OS)
大体时间:At 24 months
|
Proportion of patients alive estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment to time of death while on study. |
At 24 months
|
|
Overall Survival (OS) - Total Population
大体时间:Up to 2 years post treatment
|
Median number of months patients alive from start of treatment until death while on study will be estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions. |
Up to 2 years post treatment
|
|
12-month Overall Survival (OS) - Total Population
大体时间:At 12 months
|
Proportion of patients alive estimated by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment. |
At 12 months
|
|
24-month Overall Survival (OS) - Total Population
大体时间:At 24 months
|
Proportion of patients alive estimated by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment. |
At 24 months
|
|
ATM Status
大体时间:Up to 1 year post treatment
|
Will be assessed by immunohistochemistry (IHC) and PFS. The association between ATM and responses will be described, with a table outlining patients who achieved progressive disease, stable disease, partial or complete responses and whether they exhibited ATM expression by IHC or not. |
Up to 1 year post treatment
|
|
Peripheral Blood Mononuclear Cell gammaH2AX and p-ATM Signaling
大体时间:Up to 1 year post treatment
|
Signaling during the pharmacokinetics (PK) lead-in and in combination with BAY 1895344 will be compared with a non-parametric paired test (e.g. Wilcoxon rank test), at a significance level at p < 0.05. For tumors, this will be performed only for patients in the dose expansion cohorts. |
Up to 1 year post treatment
|
|
Tumor Multiplex Immunofluorescence Assay Signaling
大体时间:Up to 1 year post treatment
|
Signaling during the PK lead-in and in combination with BAY 1895344 will be compared with a non-parametric paired test (e.g. Wilcoxon rank test), at a significance level at p < 0.05. For tumors, this will be performed only for patients in the dose expansion cohorts. |
Up to 1 year post treatment
|
其他结果措施
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of Adverse Events
大体时间:Up to 1 year post treatment
|
Logistic regression and proportional hazards (Cox) regression will be used to assess the relationships between exposure and response and toxicity; exposure-response will be assessed within disease cohorts of sufficient size, while exposure-toxicity will pool all patients. All patients will be used for the E-R analyses. Advanced population PK methods may be employed at a later stage to assess the link between drug exposure and biological effects and efficacy. |
Up to 1 year post treatment
|
|
Status of Deoxyribonucleic Acid Damage Repair (DDR) Genes
大体时间:Up to 1 year post treatment
|
Assessed by whole exome sequencing and ribonucleic acid sequencing. The efficacy analyses will be repeated by DDR tumor mutation status, but these analyses will have limited sample sizes and will not be adequately powered for statistical comparisons. |
Up to 1 year post treatment
|
合作者和调查者
调查人员
调查人员
- 首席研究员:Liza C Villaruz、University of Pittsburgh Cancer Institute LAO
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (实际的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
其他研究编号
- NCI-2020-06482
- UM1CA186690 (美国 NIH 拨款/合同)
- NCI-2020-06482 (注册表标识符:CTRP (Clinical Trial Reporting Program))
- 10406 (其他标识符:CTEP)
- 21-060
- 10406 (其他标识符:UPMC Hillman Cancer Center LAO)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.